Pegfilgrastim in children with severe congenital neutropenia

Fioredda, Francesca, Calvillo, Michaela, Lanciotti, Marina, Lanza, Tiziana, Giunti, Laura, Castagnola, Elio, Lorenzi, Ines, Tonelli, Rossella, Ghezzi, Pietro and Dufour, Carlo (2010) Pegfilgrastim in children with severe congenital neutropenia. Pediatric Blood and Cancer, 54 (3). pp. 465-467. ISSN 1545-5017

Full text not available from this repository.


Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.

Item Type: Article
Keywords: filgrastim;pegfilgrastim; r-Hu-granulocyte-stimulating factor; severe congenital neutropenia
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine > RM Therapeutics. Pharmacology
Depositing User: Patricia Butler
Date Deposited: 02 Nov 2012 13:36
Last Modified: 05 Oct 2017 18:26
📧 Request an update